BGPT: Paper Review: Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*

Explore by Goal

Quick Explanation Copied

Core finding

In a randomized crossover study of 12 healthy men stratified by S-mephenytoin phenotype, fluvoxamine reduced total chloroguanide clearance and strongly reduced metabolite-formation clearances (cycloguanil and 4-chlorphenylbiguanide) in extensive metabolizers, but not in poor metabolizers—consistent with CYP2C19-mediated bioactivation inhibition by fluvoxamine.

Long Explanation

Paper review (mechanistic pharmacokinetics)

Question: Does fluvoxamine inhibit CYP2C19-mediated bioactivation of chloroguanide (proguanil), and is the effect present only in “extensive” S-mephenytoin metabolizers?

Design: Open randomized crossover; 12 healthy men stratified by mephenytoin S/R phenotype; fluvoxamine 100 mg/day for 8 days in period B with a day-6 200 mg chloroguanide dose; serial plasma/urine with HPLC assays.

Key quantitative outcomes (from Table/Results)

Total chloroguanide clearance (median) in extensive metabolizers: 1282 → 782 mL/min (significant).
Partial clearances (extensive metabolizers): cycloguanil formation clearance 222 → 33 mL/min, and 4-chlorphenylbiguanide formation clearance 97 → 11 mL/min (both significant in extensive metabolizers).
Poor metabolizers: no statistically significant changes in those clearances during fluvoxamine intake (i.e., a “phenocopy” pattern consistent with already-low CYP2C19 activity).
CYP3A activity control using urinary 6β-hydroxycortisol:cortisol ratio did not change, supporting that the interaction is not mediated by a major CYP3A effect in this setting.

Interactive visualizations (medians from the paper)

Note: The paper reports pharmacokinetic parameters as medians and ranges (not means). The plots below use the reported medians extracted from the provided Table/Results text.

Mechanistic interpretation (what is well-supported vs uncertain)

What the data support strongly

Phenotype-dependent sensitivity to fluvoxamine: extensive metabolizers show large decreases in metabolite-formation partial clearances, while poor metabolizers do not—matching the idea that CYP2C19 activity is already low in poor metabolizers and can be “phenocopied” by fluvoxamine in extensive metabolizers.
Specificity argument against major CYP3A effects: the urinary 6β-hydroxycortisol-to-cortisol ratio did not change, and the discussion interprets this as lack of meaningful CYP3A4 inhibition in vivo under the study conditions.

Critical uncertainties / red flags

Open-label design + small n: the study is open and includes only 12 men (with one poor metabolizer dropout in period B). That limits power, increases susceptibility to procedural/carryover artifacts, and narrows generalizability to other demographics.
PK model assumptions: clearance and partial clearance computations rely on assumptions about metabolite appearance in urine/plasma matching metabolite formation and that urine collection is complete; any violation could bias inferred “partial clearances” downward/upward.
Phenotype classification as a proxy: the study stratifies by mephenytoin S/R phenotype rather than direct CYP2C19 genotype or direct enzyme activity measurement. While that is common clinically, it remains an indirect proxy and may reflect contributions from other factors affecting the phenotype.

Does the evidence distinguish CYP2C19 vs “multiple-enzyme” mechanisms?

The paper attributes the interaction primarily to CYP2C19 inhibition and uses a CYP3A activity marker to support specificity, but it also discusses that fluvoxamine may be metabolized by CYP1A2/CYP2D6 and that inhibition might involve a combined CYP1A2+CYP2C19 effect for N-demethylation of other compounds. Those broader claims are contextual; the core chloroguanide results align well with CYP2C19 bioactivation inhibition.

Reference triangulation (within the provided dataset)

This paper’s claims about fluvoxamine’s CYP inhibition profile are consistent with other in-human studies of SSRI effects on CYP activities, e.g., reports of dose-dependent inhibition of CYP enzymes by fluvoxamine and related SSRIs.

BGPT critique in one glance

Dimension	What looks strong	What could limit certainty
Mechanism proxy	Phenotype-stratified CYP2C19 modeling using chloroguanide bioactivation intermediates and metabolite-based partial clearances.	Phenotype is an indirect proxy; no direct genotyping or direct enzyme quantification reported in the provided text.
Statistical framework	Median differences with nonparametric tests aligned to small-sample PK data reporting.	Small n and a dropout in period B reduce confidence in some comparisons (paper notes technical reasons preventing some CI calculations).
Specificity	Urinary 6β-hydroxycortisol:cortisol marker did not change, arguing against major CYP3A effects in vivo for the study conditions.	A single marker may not capture all CYP3A contributions, and the study does not directly quantify enzyme inhibition kinetics for CYP2C19 (e.g., unbound inhibitor concentration).

What would disprove or substantially change the conclusion?

Evidence for CYP2C19-independent explanations: if follow-up studies show the same chloroguanide metabolite/clearance suppression pattern with fluvoxamine in settings where CYP2C19 activity is intact (e.g., using direct CYP2C19 genotyping/phenotyping concordantly plus independent CYP3A/other CYP assessments), the attribution to CYP2C19 would weaken.
Re-analysis concerns: if the urine/plasma assumptions underlying the partial-clearance equations (metabolite formation=urinary appearance; complete urine collection; no additional metabolism) are experimentally shown to be violated enough to bias partial clearance estimation, the magnitude of CYP2C19 bioactivation inhibition could change.
Population generalizability: the sample is limited to healthy Danish males; if the interaction magnitude differs substantially by sex, ancestry, or co-morbid state, the “CYP2C19 interaction” conclusion would still be directionally plausible but would need recalibration.

Author review links

Feedback:

Updated: April 08, 2026